SynthesisTrials2026
Global landscape of yttrium-90 clinical trials: a systematic registry-based analysis.
Synthesis in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundYttrium-90 (Y-90) selective internal radiation therapy (SIRT) has emerged as an important locoregional treatment for liver and other malignancies. However, despite its expanding clinical application, the global landscape of Y-90 clinical trials has not been systematically characterized. The objective of this study was to systematically characterize the global portfolio of Y-90 clinical trials, compare liver cancer with non-liver cancer indications, and evaluate patterns of result dissemination.
methodsWe conducted a cross-sectional registry-based analysis of all Y-90 clinical trials registered on ClinicalTrials.gov from 2000 to 2025. Trial characteristics, temporal and geographic patterns, methodological features, and reported outcomes were summarized. Comparative analyses were performed between liver cancer and non-liver cancer trials. Registry entries were linked to PubMed to assess publication output.
resultsA total of 373 eligible trials were identified. Most were interventional (86.9%), treatment-focused (93.1%), and single-center (70.1%), with small sample sizes (54.2% enrolled ≤ 30 participants). Nearly half were phase 1-2 (47.7%) or phase 2-3 (45.8%), with only 6.5% reaching phase 3-4. Randomization was reported in 43.5% of trials, but masking was rare (3.4%). Geographically, studies were concentrated in North America (68.4%), with limited representation from Asia (11.5%) despite its high disease burden. Liver cancer accounted for 44.5% of trials and was more likely than non-liver cancer studies to be randomized, advanced-phase, and Asia-based. Among 93 (24.9%) discontinued trials, accrual difficulties were the leading cause (38.7%). Only 68 trials (18.2%) had published results, with efficacy and safety endpoints more consistently reported in liver cancer studies.
conclusionsY-90 research has expanded globally, especially in liver cancer, but trials remain largely small, early phase, and geographically uneven, with limited dissemination. Strengthening methodological rigor through adequately powered multicenter trials, enhancing transparency in result dissemination, and encouraging broader research efforts in high-burden regions such as Asia may help further clarify the optimal role of Y-90 in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.